<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2737">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395859</url>
  </required_header>
  <id_info>
    <org_study_id>MMT_2020_15</org_study_id>
    <nct_id>NCT04395859</nct_id>
  </id_info>
  <brief_title>Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents</brief_title>
  <acronym>COVIDIV</acronym>
  <official_title>Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal
      venous occlusion (OVR), or other conditions causing macular edema, treatments with
      anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic
      action. Patients often have injections for many years, sometimes monthly or every 2 months.

      The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked
      to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the
      ophthalmological state and the quality of life of the patients concerned, therefore it is
      relevant to analyze the consequences the breakdown of usual care in this population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic</measure>
    <time_frame>Baseline (Before confinement) and 6 months after resumption of follow-up</time_frame>
    <description>Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Patients treated with IVT before COVID19 pandemia</arm_group_label>
    <description>Treatment started at least 6 months before the French confinement for COVID19 (15th march 2020)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment</description>
    <arm_group_label>Patients treated with IVT before COVID19 pandemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection up to 1 year</intervention_name>
    <description>Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications</description>
    <arm_group_label>Patients treated with IVT before COVID19 pandemia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with repeated IVT treatment of anti-angiogenic drugs
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ocular pathology requiring repeated IVT treatment of anti-angiogenic drugs (exudative
             AMD, diabetic macular edema or secondary to retinal venous occlusion ...)

          -  Beginning of IVT treatment repeated before 10/01/2019 (6 months before the start of
             French confinement)

        Exclusion Criteria:

          -  Refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Martine MAUGET FAYSSE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Adolphe de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie YAVCHITZ, MD</last_name>
    <phone>(0)1 48 03 64 54</phone>
    <phone_ext>+33</phone_ext>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martine MAUGET FAYSSE, MD</last_name>
    <phone>(0)1 48 03 64 37</phone>
    <phone_ext>+33</phone_ext>
    <email>mmfaysse@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Pôle Vision du val d'Ouest</name>
      <address>
        <city>Ecully</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Flore DE BATS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine MAUGET FAYSSE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramin TADAYONI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre ophtalmologique Maison Rouge</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin WOLFF, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravitreal Injections</keyword>
  <keyword>Anti-angiogenics</keyword>
  <keyword>COVID19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

